Trials / Completed
CompletedNCT01057459
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
Natural Killer Cell KIR and HLA Genotypes May Predict Response to Antibody Therapy in Follicular Lymphoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 78 (actual)
- Sponsor
- Alliance for Clinical Trials in Oncology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research trial studies deoxyribonucleic acid (DNA) analysis in predicting response to antibody therapy in patients with follicular lymphoma treated on clinical trials Cancer and Leukemia Group B (CALGB)-50402 or CALGB-50701. Studying samples of blood from patients with follicular lymphoma in the laboratory may help doctors predict how well patients will respond to treatment.
Detailed description
PRIMARY OBJECTIVES: l. To test the hypothesis that killer immunoglobulin-like receptor (KIR) and human leukocyte antigen (HLA) genotypes predict overall response (partial response \[PR\], complete response\[CR\], and unconfirmed complete response \[CRu\]) within 12 months to rituximab-containing monoclonal antibody combinations in follicular lymphoma patients treated on CALGB protocols 50402 and 50701. SECONDARY OBJECTIVES: I. To test the hypothesis that KIR and HLA genotypes are associated with survival outcomes (progression-free survival \[PFS\] and overall survival \[OS\]) in follicular lymphoma patients treated with rituximab-containing monoclonal antibody combinations on CALGB protocols 50402 and 50701. OUTLINE: Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | laboratory biomarker analysis | Correlative studies |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2014-06-23
- Completion
- 2014-06-23
- First posted
- 2010-01-27
- Last updated
- 2017-06-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01057459. Inclusion in this directory is not an endorsement.